Joseph Shulman - 13 Aug 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Chief Technical Officer
Issuer ticker: RYTM
Reported as of: 13 Aug 2026
Net transaction value: -$608,210
SEC form: 4
Accepted by SEC: 17 Aug 2026, 18:00:24 UTC
Prior SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Joseph Shulman

Key filing fact

Joseph Shulman filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 17 Aug 2026.

Key facts

This page summarizes Joseph Shulman's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Aug 2026, 18:00.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: -$608,210.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001909855 Primary reporting owner

Shulman Joseph

Relationship: Chief Technical Officer
Address: C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Joseph Shulman
Signature date: 17 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RYTM transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,024
Change %: +11%
Price: $6.80^*
Shares after: 20,994
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

RYTM transaction

Common Stock

Sale

Transaction value: $608,210
Shares: -5,079
Change %: -24%
Price: $119.75
Shares after: 15,915
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Stock Options (Right to Buy)

Options Exercise

Transaction value
Shares: -2,024
Change %: -25%
Price: $0.000000^*
Shares after: 5,945
Date: 13 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,024
Exercise price: $6.80
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.

Footnote F2

The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.